SynAct Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	31.54	40.49	44.83	35.61	16.23	Upgrade
Research & Development	85.61	49.31	105.06	70.07	60.49	Upgrade
Other Operating Expenses	-0.61	-0.14	-0.04	-0.11	-0.16	Upgrade
Operating Expenses	116.54	89.67	149.84	105.57	76.56	Upgrade
Operating Income	-116.54	-89.67	-149.84	-105.57	-76.56	Upgrade
Interest Expense	-2.45	-0.82	-0.8	-0.29	-0.11	Upgrade
Interest & Investment Income	-	0.23	0.59	0.05	-	Upgrade
Currency Exchange Gain (Loss)	-	-0.57	0.33	-1.25	-0.15	Upgrade
Other Non Operating Income (Expenses)	-0	-0	-0	0	-	Upgrade
EBT Excluding Unusual Items	-118.99	-90.83	-149.72	-107.07	-76.81	Upgrade
Impairment of Goodwill	-	-	-74.56	-	-	Upgrade
Pretax Income	-118.99	-90.83	-224.28	-107.07	-76.81	Upgrade
Income Tax Expense	-8.17	-8.42	-8.47	-7.86	-7.51	Upgrade
Net Income	-110.83	-82.4	-215.81	-99.21	-69.3	Upgrade
Net Income to Common	-110.83	-82.4	-215.81	-99.21	-69.3	Upgrade
Shares Outstanding (Basic)	51	40	33	28	26	Upgrade
Shares Outstanding (Diluted)	51	40	33	28	26	Upgrade
Shares Change (YoY)	28.94%	21.81%	17.90%	6.72%	19.95%	Upgrade
EPS (Basic)	-2.17	-2.08	-6.64	-3.60	-2.68	Upgrade
EPS (Diluted)	-2.17	-2.08	-6.64	-3.60	-2.68	Upgrade
EBITDA	-	-15.09	-75.26	-	-	Upgrade
D&A For EBITDA	-	74.58	74.58	-	-	Upgrade
EBIT	-116.54	-89.67	-149.84	-105.57	-76.56	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.